Massachusetts General Hospital Cancer Center

https://www.massgeneral.org/cancer-center

 

ASCO® 2023 Insights: "Phase 1/2 TRIDENT-1 Trial - Intracranial and Systemic Efficacy of Repotrectinib in Advanced ROS1+ NSCLC & CNS Mets"

86 views
July 2, 2023
Comments 0
Login to view comments. Click here to Login